Advertisement
U.S. markets closed
  • S&P Futures

    5,210.00
    -4.75 (-0.09%)
     
  • Dow Futures

    39,210.00
    -13.00 (-0.03%)
     
  • Nasdaq Futures

    18,196.25
    -35.25 (-0.19%)
     
  • Russell 2000 Futures

    2,048.40
    -1.40 (-0.07%)
     
  • Crude Oil

    82.61
    -0.11 (-0.13%)
     
  • Gold

    2,164.20
    -0.10 (-0.00%)
     
  • Silver

    25.32
    +0.06 (+0.22%)
     
  • EUR/USD

    1.0878
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • dólar/libra

    1.2728
    -0.0001 (-0.01%)
     
  • USD/JPY

    149.2580
    +0.1600 (+0.11%)
     
  • Bitcoin USD

    65,814.59
    -2,072.15 (-3.05%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,596.29
    -144.15 (-0.36%)
     

Investors in Inhibrx (NASDAQ:INBX) have unfortunately lost 18% over the last year

This month, we saw the Inhibrx, Inc. (NASDAQ:INBX) up an impressive 96%. The stock is actually down over the last year. But at least it bettered the loss of 44% in its market.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

View our latest analysis for Inhibrx

Given that Inhibrx didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In just one year Inhibrx saw its revenue fall by 33%. That's not what investors generally want to see. The stock is down just 18% over twelve months, which is not bad all things considered. So it seems that the market saw the weak revenue coming, and isn't worried. It seems some people think the business stock will become profitable - the question is when

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Inhibrx stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Given that the broader market dropped 44% over the year, the fact that Inhibrx shareholders were down 18% isn't so bad. On the plus side, the share price has bounced a full 83% in the last three months. It could be that the share price dropped so far that the business was cheap on the numbers, but the future will ultimately determine the value of the stock. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Inhibrx has 4 warning signs (and 2 which can't be ignored) we think you should know about.

But note: Inhibrx may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement